Literature DB >> 26800676

A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey.

Rika Sakai1, Masataka Taguri2, Kumi Oshima3, Takehiko Mori4, Hiroatsu Ago5, Souichi Adachi6, Satoshi Morita7, Shuichi Taniguchi8, Takahiro Fukuda9, Kazuteru Ohashi10, Tetsuya Eto11, Koichi Miyamura12, Koji Iwato13, Naoki Kobayashi14, Heiwa Kanamori15, Yasuo Morishima16, Tokiko Nagamura-Inoue17, Hisashi Sakamaki18, Yoshiko Atsuta19, Makoto Murata20.   

Abstract

This nationwide, retrospective study compared the efficacy of cyclosporine and tacrolimus with methotrexate (CsA/MTX and TAC/MTX) for acute graft-versus-host disease (aGVHD) prevention and transplant-related outcomes. Data were obtained from the Transplant Registry Unified Management Program of the Japan Society for Hematopoietic Cell Transplantation for ≥ 16-year-old leukemia patients who received CsA/MTX or TAC/MTX after bone marrow transplantation and peripheral blood stem cell transplantation from serological HLA-matched related donors (MRD), HLA 8/8 allele-matched, or one allele-mismatched unrelated bone marrow (UBM), or 0-2 antigen-mismatched unrelated cord blood (UCB) transplantation between January 2005 and December 2009. Separate analyses were performed for each cohort. Adjusted multivariate analyses indicated that in the MRD (n = 1524) and the UBM (n = 1466) cohorts, TAC/MTX significantly reduced grade II-IV aGVHD risk (HR 0.58, P = 0.006 and HR 0.77, P = 0.015, respectively) without affecting the other transplant-related outcomes. In the UCB cohort (n = 925), TAC/MTX significantly reduced the risk of non-relapse mortality (HR 0.63, P = 0.027) and chronic GVHD (HR 0.60, P = 0.02) without significant effects on grade II-IV aGVHD (HR 0.83, P = 0.21). Our results may provide the most up-to-date data regarding GVHD prevention in Japan.

Entities:  

Keywords:  Cyclosporine; Graft-versus-host disease; Methotrexate; Tacrolimus

Mesh：

Substances：

Year:  2016        PMID： 26800676     DOI： 10.1007/s12185-016-1939-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  29 in total

Review 1.  Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis.

Authors:  J P Klein; J D Rizzo; M J Zhang; N Keiding
Journal:  Bone Marrow Transplant       Date:  2001-11       Impact factor: 5.483

Review 2.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation.

Authors:  K M Sullivan; E Agura; C Anasetti; F Appelbaum; C Badger; S Bearman; K Erickson; M Flowers; J Hansen; T Loughran
Journal:  Semin Hematol       Date:  1991-07       Impact factor: 3.851

3.  Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors.

Authors:  Takehiko Mori; Jun Kato; Takayuki Shimizu; Yoshinobu Aisa; Tomonori Nakazato; Akiko Yamane; Yukako Ono; Hiroyoshi Kunimoto; Shinichiro Okamoto
Journal:  Biol Blood Marrow Transplant       Date:  2011-06-25       Impact factor: 5.742

4.  Early immune reaction after reduced-intensity cord-blood transplantation for adult patients.

Authors:  Yukiko Kishi; Masahiro Kami; Shigesaburo Miyakoshi; Yoshinobu Kanda; Naoko Murashige; Takanori Teshima; Eiji Kusumi; Shigeo Hara; Tomoko Matsumura; Koichiro Yuji; Kazuhiro Masuoka; Atsushi Wake; Shinichi Morinaga; Mineo Kanemaru; Tatsuyuki Hayashi; Yuji Tanaka; Shuichi Taniguchi
Journal:  Transplantation       Date:  2005-07-15       Impact factor: 4.939

5.  Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine.

Authors:  M M Horowitz; D Przepiorka; P Bartels; D N Buell; M J Zhang; W E Fitzsimmons; J Erdman; C Huang; E Hodosh; R Maher; J R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  1999       Impact factor: 5.742

6.  Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation.

Authors:  A Hiraoka; Y Ohashi; S Okamoto; Y Moriyama; T Nagao; Y Kodera; A Kanamaru; H Dohy; T Masaoka
Journal:  Bone Marrow Transplant       Date:  2001-07       Impact factor: 5.483

7.  Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.

Authors:  Vanderson Rocha; Myriam Labopin; Guillermo Sanz; William Arcese; Rainer Schwerdtfeger; Alberto Bosi; Niels Jacobsen; Tapani Ruutu; Marcos de Lima; Jürgen Finke; Francesco Frassoni; Eliane Gluckman
Journal:  N Engl J Med       Date:  2004-11-25       Impact factor: 91.245

8.  Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan.

Authors:  M Yanada; N Emi; T Naoe; H Sakamaki; S Takahashi; N Hirabayashi; A Hiraoka; Y Kanda; R Tanosaki; S Okamoto; K Iwato; Y Atsuta; N Hamajima; M Tanimoto; S Kato
Journal:  Bone Marrow Transplant       Date:  2004-08       Impact factor: 5.483

9.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

10.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742
View more
  5 in total

1.  Long-term outcome and chimerism in patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation: a retrospective nationwide survey.

Authors:  Akihiro Iguchi; Yuko Cho; Hiromasa Yabe; Shunichi Kato; Koji Kato; Junichi Hara; Katsuyoshi Koh; Junko Takita; Takashi Ishihara; Masami Inoue; Kohsuke Imai; Hideki Nakayama; Yoshiko Hashii; Akira Morimoto; Yoshiko Atsuta; Tomohiro Morio
Journal:  Int J Hematol       Date:  2019-06-11       Impact factor: 2.490

2.  GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia.

Authors:  S Terakura; Y Kuwatsuka; S Yamasaki; A Wake; J Kanda; Y Inamoto; S Mizuta; T Yamaguchi; N Uchida; Y Kouzai; N Aotsuka; H Ogawa; H Kanamori; K Nishiwaki; S Miyakoshi; M Onizuka; I Amano; T Fukuda; T Ichinohe; Y Atsuta; M Murata; T Teshima
Journal:  Bone Marrow Transplant       Date:  2017-06-12       Impact factor: 5.483

3.  Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation.

Authors:  Masuho Saburi; Sumiko Kohashi; Jun Kato; Yuya Koda; Masatoshi Sakurai; Takaaki Toyama; Taku Kikuchi; Daiki Karigane; Sayako Yuda; Yusuke Yamane; Risa Hashida; Ryohei Abe; Tomonori Nakazato; Junichi Hirahashi; Masao Ogata; Shinichiro Okamoto; Takehiko Mori
Journal:  Int J Hematol       Date:  2017-05-17       Impact factor: 2.490

4.  Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia.

Authors:  Seitaro Terakura; Yachiyo Kuwatsuka; Junichi Sugita; Satoshi Takahashi; Yukiyasu Ozawa; Kazutaka Ozeki; Satoshi Yoshioka; Hirohisa Nakamae; Toshiro Kawakita; Masashi Sawa; Satoshi Morishige; Yuho Najima; Yuna Katsuoka; Emiko Sakaida; Yasuji Kouzai; Takafumi Kimura; Tatsuo Ichinohe; Takahiro Fukuda; Yoshiko Atsuta; Makoto Murata; Takanori Teshima
Journal:  Int J Hematol       Date:  2021-02-21       Impact factor: 2.490

5.  Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood transplantation.

Authors:  Toshihiro Miyamoto; Shuichiro Takashima; Koji Kato; Ken Takase; Goichi Yoshimoto; Shuro Yoshida; Hideho Henzan; Koichi Osaki; Tomohiko Kamimura; Hiromi Iwasaki; Tetsuya Eto; Takanori Teshima; Koji Nagafuji; Koichi Akashi
Journal:  Int J Hematol       Date:  2016-09-29       Impact factor: 2.490
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.